CyFlow CD105 FITC
品番 | CZ889831 | ||
---|---|---|---|
抗体名 | Anti-Hu CD105 FITC,MEM-229 | ||
包装単位 | 100 tests | ||
濃度 | - | ||
容量 | 2 ml | ||
関連製品 (アイソタイプコントロール) |
Mouse IgG2a FITC (CZ676373) |
||
反応性|交差吸着 | Human | Pig | レーザー | Blue |
抗原 | CD105, Endoglin | 最大蛍光波長 | 518 nm |
クローン | MEM-229 | 最大励起波長 | 490 to 495 nm |
ホスト | Mouse | 標識/Format | FITC |
アイソタイプ | IgG2a | 研究分野 | Immunophenotyping |
クローナリティ | monoclonal | 用途 | Flow cytometry |
Anti-Hu CD105 FITC,MEM-229
特異性
The mouse monoclonal antibody MEM-226 recognizes CD105 antigen, a 90 kDa type I integral membrane homodimer glycoprotein expressed on vascular endothelial cells (small and large vessels), activated monocytes and tissue macrophages, stromal cells of certain tissues including bone marrow, pre-B lymphocytes in fetal bone marrow and erythroid precursors in fetal and adult bone marrow; it is also present on syncytiotrophoblast on placenta throughout pregnancy.
抗原情報
CD105 (Endoglin) is a homodimeric transmembrane glycoprotein serving in presence of TGFβR-2 as a receptor for TGFβ-1 and TGFβ-3. CD105 is highly expressed on endothelial cells and promotes angiogenesis during wound healing, infarcts and in a wide range of tumours and its gene expression is stimulated by hypoxia. CD105 prevents apoptosis in hypoxic endothelial cells and also antagonizes the inhibitory effects of TGFβ-1 on vascular endothelial cell growth and migration. Normal cellular levels of CD105 are required for formation of new blood vessels.
利用方法
The reagent is designed for Flow Cytometry analysis of human blood cells. Recommended usage is 20 µl reagent / 100 µl of whole blood or 10^6 cells in a suspension. The content of a vial (2 ml) is sufficient for 100 tests.
保存方法
Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
安定性情報
Do not use after expiration date stamped on vial label.
レファレンス
• Guo B, Slevin M, Li C, Parameshwar S, Liu D, Kumar P, Bernabeu C, Kumar S: CD105 inhibits transforming growth factor‑beta‑Smad3 signalling. Anticancer·Res. 2004·May-Jun; 24(3a):1337‑45. <·PMID:·15274293·>
• Li C, Issa R, Kumar P, Hampson IN, Lopez-Novoa JM, Bernabeu C, Kumar S: CD105 prevents apoptosis in hypoxic endothelial cells. J·Cell·Sci. 2003·Jul·1; 116(13):2677‑85. <·PMID:·12746487·>
• Piao M, Tokunaga O: Significant expression of endoglin (CD105), TGFbeta‑1 and TGFbeta R‑2 in the atherosclerotic aorta: an immunohistological study. J·Atheroscler·Thromb. 2006·Apr; 13(2):82‑9. <·PMID:·16733295·>
• Plánka L, Necas A, Srnec R, Rauser P, Starý D, Jancár J, Amler E, Filová E, Hlucilová J, Kren L, Gál P: Use of allogenic stem cells for the prevention of bone bridge formation in miniature pigs. Physiol·Res. 2009; 58(6):885‑93. <·PMID:·19093735·>
• Warrington K, Hillarby MC, Li C, Letarte M, Kumar S: Functional role of CD105 in TGF‑beta1 signalling in murine and human endothelial cells. Anticancer·Res. 2005·May-Jun; 25(3B):1851‑64. <·PMID:·16158917·>
• Zhu Y, Sun Y, Xie L, Jin K, Sheibani N, Greenberg DA: Hypoxic induction of endoglin via mitogen‑activated protein kinases in mouse brain microvascular endothelial cells. Stroke. 2003·Oct; 34(10):2483‑8. <·PMID:·12947156·>
Available Safety Data Sheets
CyFlow™ monoclonal antibodies SDS CA EN